Munchen, Germany

Time filter

Source Type

Agency: European Commission | Branch: H2020 | Program: MSCA-RISE | Phase: MSCA-RISE-2014 | Award Amount: 2.43M | Year: 2015

The main objective and basic concept of our proposal is to improve intra-operative and post-operative targeted surgical probes and new detection systems for surgical intervention of cancer. The work revolves around the mobility of clinicians, scientists and technologists between twelve consortium partners and across four different countries. The goal is the implementation of inter-disciplinary, inter-sector, cross-training of personnel. As a consequence, this will serve to accelerate the development of improved imaging technologies and hybrid fluorescence/radionuclide probes for the surgical intervention of cancer. The hypothesis is that if we can develop a hybrid probe for both targeted image-guided surgery and post-operative molecular radiotherapy, we would be implementing a revolutionary imaging and therapeutic approach for oncology surgeons to help their patients by improving better overall survival and quality of life for the patient. There are four key objectives within this project: 1) synthesis of a near infra-red fluorescence (NIRF)-dye conjugated to a peptide that is targeted towards a tumour associated antigen, 2) deliver a novel clinical optoacoustic handheld camera to detect the fluorescence probe in deep tissue, 3) validate the probe/target combination across the subcellular, cellular, endoscopic and macroscopic levels with state-of-art technologies, and 4) develop the probe further by targeting a radionuclide entity to the fluorescent construct for postoperative radiotherapy. Surgeons would have a more definitive reference for resection, if the tumour margin can be clearly defined. If this can be achieved, the impact would be (a) reduced recurrence rates in patients by lowering the risk of residual tumour tissue remaining after surgery and as a consequence improve survival, (b) minimised removal of healthy tissues, c) reduced patient morbidity and hospital stay and d) significant health cost benefits.

Agency: European Commission | Branch: H2020 | Program: IA | Phase: ICT-28-2015 | Award Amount: 4.60M | Year: 2016

Multispectral Optoacoustic Tomography (MSOT) brings a revolution to bio-optical imaging. Being insensitive to photon scattering, MSOT dramatically improves upon conventional bio-optic barriers by enabling (1) three-dimensional high-resolution optical imaging deep inside tissues (several millimetres to centimetres), by (2) high-scalability, ranging from optical-resolution microscopy to acoustic-resolution optical mesoscopy and macroscopy and by (3) novel label-free anatomical, physiological and molecular contrast at the tissue and single-cell-level, based on spectrally-resolved optical absorption. MSOT, originally supported by an ERC Advanced Award (2008) (TUM: Prof. Ntziachristos), is already commercialized by iThera Medical for macroscopy with systems sold around the world for small animal imaging. In parallel, ERC MSOT funding developed a mesoscopic implementation, termed raster-scan optoacoustic mesoscopy (RSOM), which has demonstrated innovative imaging capacity at 1-5mm depths. Driven by leading dermatologists (TUM: Prof. Biedermann; SUR: Prof. Costanzo) and market leader SMEs in optoacoustic and ultrasound technology (iThera, Rayfos, Sonaxis), INNODERM will design and prototype a handheld, portable, scalable, label-free RSOM device for point-of care dermatology applications, based on recommendations developed under an ERC proof of concept grant (2013) on MSOT. INNODERM brings together key photonic & ultrasound technologies and will validate the technical and economic viability of RSOM in dermatology suites for fast diagnosis and skin disease monitoring. RSOM can go beyond the abilities of current optical or optoacoustic devices and offer a paradigm shift in dermatology imaging, substantiating successful business cases.

Agency: European Commission | Branch: FP7 | Program: CP | Phase: ICT-2011.3.5 | Award Amount: 13.40M | Year: 2012

Biophotonics offers low-cost, non-invasive, accurate, rapid alternatives to conventional diagnostic methods and has the potential to address medical needs with early detection and to reduce the cost of healthcare. FAMOS will develop a new generation of light sources with step-changes in performance beyond the state-of-the-art to radically transform biophotonic technologies for point-of-care diagnosis and functional imaging. This will enable optical diagnostics with superior sensi-tivity, specificity, reliability and clinical utility at reduced cost, heralding an imaging renaissance in Europe.FAMOS addresses optical imaging from molecular over (sub)cellular to individual organs, with no gap in the arsenal of diagnostic tools for medical end-users. The world-class multidisciplinary FA-MOS team of 7 leading academic institutions and 10 top SMEs has unique complementary knowledge of optical coherence tomography, adaptive optics, photoacoustic tomography, coherent anti-stokes Raman scattering, multiphoton tomography as well as swept-source, diode-pumped ultrafast and tuneable nanosecond pulse lasers. Combinations of some techniques will offer multi-modal solutions to diagnostic needs that will exploit and enhance the benefits of each modality. FAMOS technologies have wide applicability, but our specific focus is on diagnosis in ophthalmol-ogy and oncology. Partnerships with leading innovative clinical users will enable preclinical evalua-tion.The objectives of FAMOS are:\tDevelop new light sources with a step-change in performance (2-3 times more compact and up to 3-4 times cheaper diode pumped Ti:sapphire, 4-10 times faster swept sources and tuneable nanosecond pulse sources)\tIntegrate these with optical imaging for a step-change in diagnosis (2-5 times better resolution cellular retinal imaging with more than 10 times larger field of view, up to 10 times enhanced penetration single source subcellular morphologic imaging, increased selectivity of intrinsic mo-lecular sensing as well as several frames per second deep tissue functional tomography\tPerform preclinical studies to demonstrate novel or improved ophthalmic and skin cancer diag-nosis establishing novel biomarkers (melanocyte shape, NADPH, melanin concentration, Hb/HbO2 as well as lipid, water and DNA/RNA concentration)\tEnable exceptional commercial opportunities for SMEs\tProvide state-of-the-art academic training

Wu W.,Nanjing University | Driessen W.,iThera Medical | Jiang X.,Nanjing University
Journal of the American Chemical Society | Year: 2014

Dendrimers have several featured advantages over other nanomaterials as drug carriers, such as well-defined structure, specific low-nanometer size, and abundant peripheral derivable groups, etc. However, these advantages have not been fully exploited yet to optimize their biological performance, especially tumor penetration, which is a shortcoming of current nanomaterials. Here we show the syntheses of a new class of oligo(ethylene glycol) (OEG)-based thermosensitive dendrimers up to the fourth generation. Each dendrimer shows monodisperse structure. OEG/poly(ethylene glycol) (PEG) moieties with different precise lengths were introduced to the periphery of the fourth-generation dendrimer followed by an antitumor agent, gemcitabine (GEM). The biodistributions of the GEM-conjugated dendrimers were investigated by micro positron emission tomography and multispectral optoacoustic tomography imaging techniques and compared with that of GEM-conjugated poly(amidoamine) (PAMAM). The GEM-conjugated dendrimer with the longest peripheral PEG segments exhibited the most desirable tumor accumulation and penetration and thus had significantly higher antitumor activity than the GEM-conjugated PAMAM. © 2014 American Chemical Society.

Buehler A.,Helmholtz Center Munich | Kacprowicz M.,iThera Medical | Taruttis A.,Helmholtz Center Munich | Taruttis A.,TU Munich | And 2 more authors.
Optics Letters | Year: 2013

Multispectral optoacoustic tomography (MSOT) of functional and molecular contrast has the potential to find broad deployment in clinical practice. We have developed the first handheld MSOT imaging device with fast wavelength tuning achieving a frame rate of 50 Hz. In this Letter, we demonstrate its clinical potential by dynamically resolving multiple disease-relevant tissue chromophores, including oxy-/deoxyhemoglobin, and melanin, in human volunteers. © 2013 Optical Society of America.

Agency: GTR | Branch: EPSRC | Program: | Phase: Research Grant | Award Amount: 8.20K | Year: 2015

BACKGROUND Radiotherapy (RT) is one of the most efficient tools in cancer treatment, and clinical RT is evolving considerably with technological advances in delivery and treatment planning. A key component of modern RT is enhanced image guidance, needed for precise tumour targeting, therapy monitoring and therapy assessment. To achieve the best care for patients with cancer receiving RT, developments are needed to optimise the physics and technology of image guidance. This should include the exploitation of new discoveries in targeted drugs and nanoparticles that increase tumour sensitivity to radiation, and of synergisms between RT and other physical therapies such as high intensity focused ultrasound (HIFU), hyperthermia and ultrasound (US) microbubble damage to tumour vasculature. These novel approaches to image guided RT must first be investigated in a preclinical setting before the most promising techniques can be translated to clinical studies. For this work, the integration of the best preclinical therapy with the best preclinical imaging will play a crucial role. To replicate the sophistication of clinical radiation treatment methods for preclinical research requires significant technological advances to systems such as the small animal radiation research platform (SARRP), including the integration of reliable methods for image guidance. US imaging methods, including multispectral optoacoustic tomography (MSOT), offer the potential for improved and complementary image guidance capability relative to existing methods based on x-ray, nuclear medicine (NM) and magnetic resonance (MR) imaging. RESEARCH We aim to (a) develop an integrated SARRP-MSOT image guided preclinical RT facility and (b) use it to aid the development and optimisation of novel imaging methods and probes, and new therapeutic synergisms, to either evaluate or enhance effects of radiation on cancer cells. Over a five year period, 7 physics teams will conduct research in the following areas. The SARRP will be modified for co-registration with MSOT and for preclinical tumour treatment using the most advanced methods employed clinically, under image guidance. We will develop methods for accurate determination of applied radiation dose and integrate a special x-ray detector for quantitative computed tomography able to distinguish tissue types and detect dose-enhancing nanoparticles. We will investigate possibilities to exploit therapeutic synergisms by integrating US therapy with the SARRP. We will modify the MSOT device for US microbubble imaging, using MSOT imaging of blood supply and oxygenation to optimise RT and US treatment combinations, investigating the use of US microbubbles to enhance RT, and developing dose parameters for combined physical therapies. Imaging techniques and probe chemistry will be developed and optimised for MSOT prediction of enhancement of targeted radiosensitisation, indication of prognosis and assessment of tumour response. Performance will be compared with NM probes and MR imaging techniques. Methods for US guidance of advanced RT treatments will be optimised by developing co-registration of US images with NM, MR and MSOT images that predict radiosensitivity, and developing and evaluating US-based motion compensated dose delivery and imaging to identify the distribution of viable tumour cells as treatment progresses to facilitate treatment adaptation to avoid relapse. Finally, cross-institutional collaborative research in the above and other areas will be fostered by making the integrated facility available to external users and by running workshops for sharing technical and scientific information, and planning, executing and reporting on joint studies.

Agency: European Commission | Branch: H2020 | Program: MSCA-ITN-ETN | Phase: MSCA-ITN-2016 | Award Amount: 3.90M | Year: 2016

FBI fosters education of ESRs on an emerging, multimodal imaging platform and its translation into clinical and biological applications. In FBI, 15 ESRs are trained at world-leading European academic institutions and companies, thus forming strong interdisciplinary relations between industry, technical sciences and clinical end-users. Optical imaging has huge potential to address unmet clinical needs by combining non-invasive and real-time capture of biomedical information; thus enabling earlier onset of treatment, reduced therapy costs, reduced recurrence rates, and improved clinical outcomes. Up to now, optical modalities were applied as standalone techniques each targeting one biomarker. Recently it has been shown that diagnosis is significantly improved by combining different contrast mechanisms simultaneously in a multimodal approach, i.e., staging and grading of lesions is feasible. FBI proposes to combine a selection of modalities depending on the targeted disease. Suspicious lesions are analysed with optical coherence tomography, optoacoustic tomography, multi-photon tomography, and Raman spectroscopy to provide morphological, label-free microangiography, and intrinsic biochemical information, respectively. An important issue is the need for endoscopy: combining said modalities into endoscopes is challenging due to the integration of different imaging concepts, scanning and detection methods, and laser sources. Accordingly, there is a huge need for effectively translating these technical solutions to industry and clinics, which traditionally is restricted by lack of understanding of applications or limited knowledge of new technology. All these barriers are addressed by FBI through research and development of novel photonic components and systems, through educating ESRs in understanding clinical, biological and commercial challenges, and through developing tailored technical solutions and efficient translation of technology within a strong network.

The invention relates to a handheld device (10) and an according method for optoacoustic imaging of an object, comprising an irradiation unit (2b) for irradiating the object with electromagnetic radiation (5), in particular light, and a detector unit (1 a, 1 b) for detecting acoustic, in particular ultrasonic, waves generated in the object upon irradiation with electromagnetic radiation (5), wherein the detector unit (1 a, 1 b) comprises an array (1 a) of detector elements. In order to ensure an acquisition of high-quality tomographic optoacoustic images from different depths within the object at a simple overall design, the handheld device (19) is provided with a recess (6), in which the irradiation unit (2b) and the array (1 a) of detector elements are provided, wherein the detector elements are arranged in the recess (6) such that the surface normals of at least a part of the detector elements are directed to a region of interest on or within the object.

The present disclosure relates to a handheld device and an according method for optoacoustic imaging of an object, comprising an irradiation unit for irradiating the object with electromagnetic radiation, for example, light, and a detector unit for detecting acoustic, for example, ultrasonic, waves generated in the object upon irradiation with electromagnetic radiation, wherein the detector unit comprises an array of detector elements. In order to facilitate an acquisition of high-quality tomographic optoacoustic images from different depths within the object at a simple overall design, the handheld device may be provided with a recess, in which the irradiation unit and the array of detector elements are provided, wherein the detector elements are arranged in the recess such that the surface normals of at least a part of the detector elements are directed to a region of interest on or within the object.

Loading iThera Medical collaborators
Loading iThera Medical collaborators